ASH: Lower Rate of Sickle Cell Pain Crises With Crizanlizumab

This article originally appeared here.
Share this content:
ASH: Lower Rate of Sickle Cell Pain Crises With Crizanlizumab
ASH: Lower Rate of Sickle Cell Pain Crises With Crizanlizumab

MONDAY, Dec. 5, 2016 (HealthDay News) -- High-dose crizanlizumab treatment is associated with a significantly lower rate of sickle cell-related pain crises than placebo, according to a study published online Dec. 3 in The New England Journal of Medicine to coincide with the annual meeting of the American Society of Hematology, held from Dec. 3 to 6 in San Diego.

Kenneth I. Ataga, M.B.B.S., from the University of North Carolina at Chapel Hill, and colleagues conducted a phase 2 trial involving patients with sickle cell disease who were randomized to receive low-dose crizanlizumab, high-dose crizanlizumab, or placebo administered intravenously over a period of 52 weeks. A total of 198 patients at 60 sites underwent randomization.

The researchers found that the median rate of crises per year was 1.63 and 2.98 for high-dose crizanlizumab versus placebo, respectively. The median time to the first crisis and to the second crisis was significantly longer with high-dose crizanlizumab therapy than placebo (4.07 versus 1.38 months and 10.32 versus 5.09 months). The median rate of uncomplicated crises per year was 1.08 and 2.91 for high-dose crizanlizumab versus placebo, respectively.

"In patients with sickle cell disease, crizanlizumab therapy resulted in a significantly lower rate of sickle cell-related pain crises than placebo and was associated with a low incidence of adverse events," the authors write.

The study was funded by Selexys Pharmaceuticals.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Recent Decline in Prescription Opioid Use Among U.S. Teens

Recent Decline in Prescription Opioid Use Among U.S. ...

Lifetime prevalence of use peaked in 1989, 2002, and remained stable until decline in 2013 to 2015

Treatment Seeking Low Among Teens With Eating Disorders

Treatment Seeking Low Among Teens With Eating Disorders

Those with counter-stereotypic presentation even less likely to seek treatment

Optical Clearing Agent Ups No. of Laser Passes in Tattoo Removal

Optical Clearing Agent Ups No. of Laser Passes ...

Findings based on number of laser passes during a five-minute tattoo removal session

is free, fast, and customized just for you!

Already a member?

Sign In Now »